INTRODUCTION: The prevalence of smoking among people with schizophrenia in the United States is about 3 times that of the general population. Novel approaches are needed to reduce rates of smoking-related morbidity and mortality among these smokers. METHODS: This study used a within-subjects design to investigate the separate and combined effects of sensorimotor replacement for smoking (very low nicotine content [VLNC] cigarettes vs. no cigarettes) and transdermal nicotine replacement (42 mg nicotine [NIC] vs. placebo [PLA] patches) in smokers with schizophrenia (SS; n = 30) and control smokers without psychiatric illness (CS; n = 26). Each session contained a 5-hr controlled administration period in which participants underwent the following conditions, in counterbalanced order: VLNC + NIC, VLNC + PLA, no cigarettes + NIC, no cigarettes + PLA, usual-brand cigarettes + no patches. Next, participants completed measures of cigarette craving, nicotine withdrawal, smoking habit withdrawal, and cigarette subjective effects, followed by a 90-min period of ad libitum usual-brand smoking. RESULTS: Smoking VLNC cigarettes during the controlled administration periods reduced cigarette craving, nicotine withdrawal symptoms, habit withdrawal symptoms, and usual-brand smoking in SS and CS relative to the no cigarette conditions. VLNC cigarettes were well accepted by both groups and did not affect psychiatric symptom levels in SS. Transdermal nicotine significantly reduced cigarette craving but did not affect usual-brand smoking. CONCLUSIONS: These findings suggest that reducing the nicotine content of cigarettes to nonaddictive levels may be a promising approach for reducing nicotine dependence among people with schizophrenia.
RCT Entities:
INTRODUCTION: The prevalence of smoking among people with schizophrenia in the United States is about 3 times that of the general population. Novel approaches are needed to reduce rates of smoking-related morbidity and mortality among these smokers. METHODS: This study used a within-subjects design to investigate the separate and combined effects of sensorimotor replacement for smoking (very low nicotine content [VLNC] cigarettes vs. no cigarettes) and transdermal nicotine replacement (42 mg nicotine [NIC] vs. placebo [PLA] patches) in smokers with schizophrenia (SS; n = 30) and control smokers without psychiatric illness (CS; n = 26). Each session contained a 5-hr controlled administration period in which participants underwent the following conditions, in counterbalanced order: VLNC + NIC, VLNC + PLA, no cigarettes + NIC, no cigarettes + PLA, usual-brand cigarettes + no patches. Next, participants completed measures of cigarette craving, nicotine withdrawal, smoking habit withdrawal, and cigarette subjective effects, followed by a 90-min period of ad libitum usual-brand smoking. RESULTS: Smoking VLNC cigarettes during the controlled administration periods reduced cigarette craving, nicotine withdrawal symptoms, habit withdrawal symptoms, and usual-brand smoking in SS and CS relative to the no cigarette conditions. VLNC cigarettes were well accepted by both groups and did not affect psychiatric symptom levels in SS. Transdermal nicotine significantly reduced cigarette craving but did not affect usual-brand smoking. CONCLUSIONS: These findings suggest that reducing the nicotine content of cigarettes to nonaddictive levels may be a promising approach for reducing nicotine dependence among people with schizophrenia.
Authors: Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller Journal: Tob Control Date: 2010-10 Impact factor: 7.552
Authors: Jill M Williams; Kunal K Gandhi; Shou-En Lu; Supriya Kumar; Marc L Steinberg; Brett Cottler; Neal L Benowitz Journal: Drug Alcohol Depend Date: 2011-05-18 Impact factor: 4.492
Authors: Andrea H Weinberger; Kristi A Sacco; Cerissa L Creeden; Jennifer C Vessicchio; Peter I Jatlow; Tony P George Journal: Schizophr Res Date: 2007-02-09 Impact factor: 4.939
Authors: Stephen T Higgins; Cecilia L Bergeria; Danielle R Davis; Joanna M Streck; Andrea C Villanti; John R Hughes; Stacey C Sigmon; Jennifer W Tidey; Sarah H Heil; Diann E Gaalema; Maxine L Stitzer; Jeff S Priest; Joan M Skelly; Derek D Reed; Janice Y Bunn; Morgan A Tromblee; Christopher A Arger; Mollie E Miller Journal: Prev Med Date: 2018-04-04 Impact factor: 4.018
Authors: Stephen T Higgins; Allison N Kurti; Marissa Palmer; Jennifer W Tidey; Antonio Cepeda-Benito; Maria R Cooper; Nicolle M Krebs; Lourdes Baezconde-Garbanati; Joy L Hart; Cassandra A Stanton Journal: Prev Med Date: 2019-05-02 Impact factor: 4.018
Authors: M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492
Authors: Tracy T Smith; Joseph S Koopmeiners; Katelyn M Tessier; Esa M Davis; Cynthia A Conklin; Rachel L Denlinger-Apte; Tonya Lane; Sharon E Murphy; Jennifer W Tidey; Dorothy K Hatsukami; Eric C Donny Journal: Am J Prev Med Date: 2019-10 Impact factor: 5.043
Authors: Eric C Donny; Dorothy K Hatsukami; Neal L Benowitz; Alan F Sved; Jennifer W Tidey; Rachel N Cassidy Journal: Prev Med Date: 2014-06-23 Impact factor: 4.018